Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases

1 Oct 2017

Abstract excerpt

BACKGROUND: Anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements represent two most frequent fusion targets in lung adenocarcinoma. Our study was intended to explore the clinicopathological characteristics, coexistence and treatment of ALK/ROS1-rearranged patients of lung adenocarcinoma without epidermal growth factor receptor (EGFR) mutation. METHODS: Patients with wild-type EGFR mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29268402
DOI: 10.21037/jtd.2017.09.79

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 casesPMID 29268402Read ↗

Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients.Semantic proximity Read ↗

EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.Semantic proximity Read ↗

[Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].Semantic proximity Read ↗

Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.Semantic proximity Read ↗

Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: A case report and literature review.Semantic proximity Read ↗

Evaluation of ROS1 expression and rearrangements in a large cohort of early- stage lung cancerSemantic proximity Read ↗

High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.Semantic proximity Read ↗

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to DateSemantic proximity Read ↗

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAFSemantic proximity Read ↗

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.Semantic proximity Read ↗

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.Semantic proximity Read ↗

“Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer”Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.